A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
about
Translatability scoring in drug development: eight case studiesDirect thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationDirect thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacementThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsReview article: Venous thromboembolism after total joint replacementAnithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapyPharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacementReversing the anticoagulation effects of dabigatran.Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.Beyond heparin and warfarin: the new generation of anticoagulants.Latest medical treatment strategies for venous thromboembolism.Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Direct thrombin inhibitors.Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyNonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgeryDiet as prophylaxis and treatment for venous thromboembolism?Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timePharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Hidden blood loss and its influential factors after total hip arthroplasty.Thromboembolic disease after knee arthroplasty is rare in Southern Iran.Pharmacological basis and clinical evidence of dabigatran therapy.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersEffects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials.Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.The status of new anticoagulants.Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.Epidemiology of total hip and knee replacement: a cross-sectional study.A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.
P2860
Q22241760-69B4A6E6-D91F-422E-BA1A-097B620BB523Q24197843-91DBD01C-9BFD-49A5-A78E-7494414F7DD2Q24235993-E4B1F5AA-D976-4C83-B40A-29B7C52DA2FCQ26828439-37EA1805-43EB-48B4-B3A2-924BC790351CQ26995635-25CF6E29-45E0-4B15-9308-E5D96A097F76Q27006824-2571ACCE-9CC3-48A1-AF01-1D0AEEEC5092Q28220433-580AE30B-9409-4FE9-9A4D-4273D97A37F7Q28245267-8AF755FB-D667-4F2F-B6E3-096224C03EBDQ30400249-069AED73-4C1C-44B4-9629-755468764B18Q30680968-EF95C6C2-9C02-4FA8-AA29-D821E745BA34Q33374258-B42144BC-F0DA-4918-B309-8013A76A4A4BQ33375535-C39BDD60-6E6B-4AB3-9439-F4A676BED5F2Q33381801-B95B72BB-C04B-4B37-9313-AEDA45336984Q33389966-7BF2E2BD-1798-474C-B750-088345EA1DF4Q33393692-D0A71F41-E305-4EC8-B55B-B872EC450946Q33402042-1ABB7C9F-1F89-4AEC-A5A6-22A31DC2473FQ33891915-188D2E8E-FF0C-429E-8CB9-84ED0B97DC8DQ34058973-4F1EB936-E977-4875-976B-C9795F139800Q34078303-34BD3DBB-0CF2-4417-8277-C11AE9FF0B46Q34469002-F36D02ED-F397-404A-BA93-98F933C3DC8FQ34549913-A3FFA5C5-0BF2-48AE-B41D-B948A1D43397Q34561970-3126322E-7DEB-4F7D-9A54-277A18454CAEQ34564159-F295CA29-F126-4487-AF1A-63602EA47240Q34571082-08185EFB-A365-4F5B-B220-02B14CEADD8BQ34611004-715A1B26-EC37-4E0E-AE33-F2266C715A0EQ34638063-76AF2119-B871-482D-ABDB-F53D70C7429EQ35201182-D5DE588B-D584-4F87-AC04-0012CA7D19F9Q35573560-BE3EEA6B-716D-4124-9FA1-061E081503C7Q35685099-A01944B2-0E78-409F-ABD1-D49CE30D7194Q35739671-4523B3C5-C156-4376-9827-2859BEF139EDQ35827856-44C8CB6F-D889-4422-B96E-7295FCC17CE7Q35851245-00082892-DE6C-46A2-9E89-C97B536B2E01Q36240036-A701587D-A064-4402-B71D-BADAC5E9E64AQ36286611-3DA1495C-C439-4D06-A5F3-80CD7AD9FF16Q36321989-0E5CC9DA-2333-4363-B342-B23C22FAD95DQ36520745-6CA99B20-B188-4777-A9B9-B616E4CA530FQ36548878-BA9B10F4-171C-4BE4-92B8-3C5C212EFAA6Q36791747-F8C68B14-86E6-4BE5-8045-6172330B7F6DQ36916787-DDDE42DB-EA00-4139-BA48-EAA5291989C2Q36988011-3F24BD7E-C3D7-4932-A22F-555BD24A9C69
P2860
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A new oral direct thrombin inh ...... he BISTRO II randomized trial.
@en
type
label
A new oral direct thrombin inh ...... he BISTRO II randomized trial.
@en
prefLabel
A new oral direct thrombin inh ...... he BISTRO II randomized trial.
@en
P2093
P2860
P1476
A new oral direct thrombin inh ...... he BISTRO II randomized trial.
@en
P2093
B I Eriksson
BISTRO II Study Group
F Piovella
H R Büller
J Stangier
N Rosencher
P2860
P304
P356
10.1111/J.1538-7836.2004.01100.X
P577
2005-01-01T00:00:00Z